Exelixis, Inc. (NASDAQ:EXEL) CFO Christopher J. Senner Sells 29,314 Shares

Exelixis, Inc. (NASDAQ:EXELGet Free Report) CFO Christopher J. Senner sold 29,314 shares of the business’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $36.14, for a total transaction of $1,059,407.96. Following the completion of the transaction, the chief financial officer now owns 779,607 shares in the company, valued at approximately $28,174,996.98. This trade represents a 3.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Exelixis Stock Performance

Shares of EXEL opened at $37.53 on Thursday. The firm has a market capitalization of $10.50 billion, a PE ratio of 21.20, a P/E/G ratio of 1.13 and a beta of 0.53. The stock has a 50 day simple moving average of $34.34 and a 200 day simple moving average of $31.50. Exelixis, Inc. has a 52-week low of $20.14 and a 52-week high of $37.64.

Exelixis (NASDAQ:EXELGet Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. Equities research analysts predict that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Forum Financial Management LP bought a new stake in Exelixis in the 4th quarter valued at approximately $241,000. GF Fund Management CO. LTD. bought a new stake in shares of Exelixis in the fourth quarter worth $200,000. Neo Ivy Capital Management boosted its holdings in Exelixis by 427.8% during the fourth quarter. Neo Ivy Capital Management now owns 53,892 shares of the biotechnology company’s stock worth $1,794,000 after purchasing an additional 43,682 shares during the last quarter. JT Stratford LLC bought a new position in Exelixis in the fourth quarter valued at $288,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Exelixis by 4.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 844,345 shares of the biotechnology company’s stock valued at $28,117,000 after buying an additional 33,804 shares during the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on EXEL. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Exelixis in a research note on Thursday, February 13th. Oppenheimer lowered Exelixis from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $41.00 to $33.00 in a research note on Friday, January 24th. JMP Securities restated a “market outperform” rating and set a $41.00 target price on shares of Exelixis in a report on Thursday, January 23rd. Truist Financial lifted their price target on Exelixis from $42.00 to $43.00 and gave the company a “buy” rating in a report on Monday, January 27th. Finally, Bank of America lowered shares of Exelixis from a “buy” rating to a “neutral” rating and increased their price objective for the stock from $35.00 to $39.00 in a report on Tuesday, December 17th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $37.24.

Check Out Our Latest Report on EXEL

Exelixis Company Profile

(Get Free Report)

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

Read More

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.